focus -WSS

focus

author：fashion 2025-09-30 14:49:04 Page View：8

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： H5N1 virus can be tracked in retail milk, scientists say
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Women's World Cup brings attention to abuse in soccer

FILE-RepublicofIreland'sSineadFarrelly,center,greetsplayersaftertheteam'smatchwiththeUnitedStatesina

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Listen: More tumult at BIO & coercive care for sickle cell patients

Howdoesadrugindustrylobbyinggroupmoveforwardafteryearsofupheaval,includinghavingfourCEOsinfouryears?

focus

comprehensive

explore

Listen: More tumult at BIO & coercive care for sickle cell patients